title: A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.
abstract: Medications indicated for helminthes and other parasitic infections are frequently being used in mass populations in endemic areas. Currently, there is a lack of guidance for clinicians on how to appropriately manage drug interactions when faced with patients requiring short-term anthelmintic therapy with albendazole or mebendazole while concurrently taking other agents. The objective of this review was to systematically summarize and evaluate published literature on the pharmacokinetics of albendazole or mebendazole when taken with other interacting medications. A search of MEDLINE (1946 to October 2014), EMBASE (1974 to October 2014), International Pharmaceutical Abstracts (1970 to October 2014), Google, and Google Scholar was conducted for articles describing the pharmacokinetics of albendazole or mebendazole when given with other medications (and supplemented by a bibliographic review of all relevant articles). Altogether, 17 articles were included in the review. Studies reported data on pharmacokinetic parameters for albendazole or mebendazole when taken with cimetidine, dexamethasone, ritonavir, phenytoin, carbamazepine, phenobarbital, ivermectin, praziquantel, diethylcarbamazine, azithromycin, and levamisole. Cimetidine increased the elimination half-life of albendazole and maximum concentration (Cmax) of mebendazole; dexamethasone increased the area under the plasma concentration-time curve (AUC) of albendazole; levamisole decreased the Cmax of albendazole; anticonvulsants (phenytoin, phenobarbital, carbamazepine) decreased the AUC of albendazole; praziquantel increased the AUC of albendazole; and ritonavir decreased the AUC of both albendazole and mebendazole. No major interactions were found with ivermectin, azithromycin, or diethylcarbamazine. Future research is required to clarify the clinical relevance of the interactions observed.
authors.affiliation: College of Pharmacy, Qatar University, P.O. Box 2713, Doha, Qatar, shane.pawluk@qu.edu.qa.
authors.forename: Shane Ashley
authors.initials: SA
authors.lastname: Pawluk
authors.forename: Craig Allan
authors.initials: CA
authors.lastname: Roels
authors.forename: Kyle John
authors.initials: KJ
authors.lastname: Wilby
authors.forename: Mary H H
authors.initials: MH
authors.lastname: Ensom
mesh_terms: D000328:Adult; D015766:Albendazole / Q000493:pharmacokinetics*; D000871:Anthelmintics / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008463:Mebendazole / Q000493:pharmacokinetics*
chemical_list: D000871:Anthelmintics; D008463:Mebendazole; D015766:Albendazole